These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 36089643)
21. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion. O'Reilly EM; Hechtman JF Ann Oncol; 2019 Nov; 30(Suppl_8):viii36-viii40. PubMed ID: 31605106 [TBL] [Abstract][Full Text] [Related]
22. Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland. Zhang W; Schmitz AA; Kallionpää RE; Perälä M; Pitkänen N; Tukiainen M; Alanne E; Jöhrens K; Schulze-Rath R; Farahmand B; Zong J Acta Oncol; 2024 Jul; 63():542-551. PubMed ID: 38967220 [TBL] [Abstract][Full Text] [Related]
23. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Demetri GD; Antonescu CR; Bjerkehagen B; Bovée JVMG; Boye K; Chacón M; Dei Tos AP; Desai J; Fletcher JA; Gelderblom H; George S; Gronchi A; Haas RL; Hindi N; Hohenberger P; Joensuu H; Jones RL; Judson I; Kang YK; Kawai A; Lazar AJ; Le Cesne A; Maestro R; Maki RG; Martín J; Patel S; Penault-Llorca F; Premanand Raut C; Rutkowski P; Safwat A; Sbaraglia M; Schaefer IM; Shen L; Serrano C; Schöffski P; Stacchiotti S; Sundby Hall K; Tap WD; Thomas DM; Trent J; Valverde C; van der Graaf WTA; von Mehren M; Wagner A; Wardelmann E; Naito Y; Zalcberg J; Blay JY Ann Oncol; 2020 Nov; 31(11):1506-1517. PubMed ID: 32891793 [TBL] [Abstract][Full Text] [Related]
24. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?]. Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719 [TBL] [Abstract][Full Text] [Related]
25. Practical instructions for testing and targeted therapy in adult patients with solid tumours with NTRK gene fusion in common clinical practice. Büchler T; Dundr P; Fínek J; Kiss I; Matěj R; Melichar B; Michal M; Petruželka L Klin Onkol; 2020; 33(6):414-419. PubMed ID: 33685189 [TBL] [Abstract][Full Text] [Related]
26. NTRK gene fusion testing and management in lung cancer. Repetto M; Chiara Garassino M; Loong HH; Lopez-Rios F; Mok T; Peters S; Planchard D; Popat S; Rudzinski ER; Drilon A; Zhou C Cancer Treat Rev; 2024 Jun; 127():102733. PubMed ID: 38733648 [TBL] [Abstract][Full Text] [Related]
27. Diagnosis and management of TRK fusion cancer. Kummar S; Italiano A; Brose MS; Carlson JJ; Sullivan SD; Lassen U; Federman N Am J Manag Care; 2022 Jan; 28(2 Suppl):S15-S25. PubMed ID: 35201680 [TBL] [Abstract][Full Text] [Related]
28. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib. Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380 [TBL] [Abstract][Full Text] [Related]
29. Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology. Rohrberg KS; Lassen U Drugs; 2021 Mar; 81(4):445-452. PubMed ID: 33400240 [TBL] [Abstract][Full Text] [Related]
30. TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting. Bazhenova L; Lokker A; Snider J; Castellanos E; Fisher V; Fellous M; Nanda S; Zong J; Keating K; Jiao X Target Oncol; 2021 May; 16(3):389-399. PubMed ID: 33893941 [TBL] [Abstract][Full Text] [Related]
31. NTRK fusions in thyroid cancer: Pathology and clinical aspects. Ma Y; Zhang Q; Zhang K; Liang Y; Ren F; Zhang J; Kan C; Han F; Sun X Crit Rev Oncol Hematol; 2023 Apr; 184():103957. PubMed ID: 36907364 [TBL] [Abstract][Full Text] [Related]
32. The promise of TRK inhibitors in pediatric cancers with NTRK fusions. Blauel ER; Laetsch TW Cancer Genet; 2022 Apr; 262-263():71-79. PubMed ID: 35108663 [TBL] [Abstract][Full Text] [Related]
33. Detection of Cuello M; García-Rivello H; Huamán-Garaicoa F; Irigoyen-Piñeiros P; Lara-Torres CO; Rizzo MM; Ticona-Castro M; Trejo R; Zoroquiain P Future Oncol; 2023 Dec; 19(40):2669-2682. PubMed ID: 38088163 [No Abstract] [Full Text] [Related]
34. Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer. Dyrbekk APH; Warsame AA; Suhrke P; Ludahl MO; Zecic N; Moe JO; Lund-Iversen M; Brustugun OT Clin Exp Med; 2024 Jan; 24(1):10. PubMed ID: 38240952 [TBL] [Abstract][Full Text] [Related]
35. TRK inhibitors in TRK fusion-positive cancers. Drilon A Ann Oncol; 2019 Nov; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935 [TBL] [Abstract][Full Text] [Related]
36. Testing algorithm for identification of patients with TRK fusion cancer. Penault-Llorca F; Rudzinski ER; Sepulveda AR J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837 [TBL] [Abstract][Full Text] [Related]